Quantitative proteomics profiling reveals activation of mTOR pathway in trastuzumab resistance

Trastuzumab is an antibody-based therapy drug targeting HER2-overexpressing tumors. While it has been proven to be very successful initially, most patients eventually develop resistance to trastuzumab. The mechanism of drug resistance is not well understood. Identifying pathways that mediate trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenhu, Chang, Jinxia, Liu, Mingwei, Yuan, Jiangbei, Zhang, Jinqiang, Qin, Jun, Xia, Xuefeng, Wang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542228/
https://www.ncbi.nlm.nih.gov/pubmed/28507275
http://dx.doi.org/10.18632/oncotarget.17415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542228/
https://www.ncbi.nlm.nih.gov/pubmed/28507275
http://dx.doi.org/10.18632/oncotarget.17415

Ejemplares similares